

Tuesday, 17 August

7.30-8.30 **Registration** (PHAA Desk, Foyer G)

8.30-10.30 **Welcome: Professor Mike Daube**
Opening Address: The Hon Mark Butler MP, Parliamentary Secretary for Health
(Hall B & C)

Plenary 1 - Influenza: Pandemic and beyond
Chair: Professor Mike Daube
sponsored by Sanofi Pasteur



Prof James F Bishop AO - Abstract: TBA
A/Prof Peter Richmond - Abstract: TBA
Prof Elizabeth Miller - Pandemic influenza – the European experience and lessons learned

10.30-11.00 **Morning Tea** (Hall G)

11.00-12.30 **Concurrent Sessions 1**

Pandemic Influenza (Hall B & C) Chair: Heath Kelly

- 11.00-11.15 1. Why do I need it? Public Perceptions towards the pandemic (H1N1) 2009 vaccine - H Seale
- 11.15-11.30 2. Hypothetical versus real pandemic – evaluating community acceptance of the public health response - H Marshall
- 11.30-11.45 3. Implementing weekend school Pandemic (H1N1) 2009 vaccination clinics in Southern Queensland - L Waters
- 11.45-12.00 4. Training program for South Australian Health Care Workers to deliver H1N1 Pandemic Influenza vaccine - A Newbound
- 12.00-12.15 5. Immunogenicity and Safety of Monovalent 2009 Influenza A (H1N1) Vaccine in Children - J McVernon
- 12.15-12.30 6. Implementing Pandemic H1N1 2009 influenza vaccination – a national perspective - J Bryant & B Harvey

Human Papillomavirus 1 (Meeting Room1 & 2) Chair: Julia Brotherton

- 11.00-11.15 1. The Efficacy of Quadrivalent HPV (Types 6/11/16/18) Vaccine against HPV-Related Genital Disease and Infection in Young Men - R Hillman
- 11.15-11.30 2. Quadrivalent HPV Vaccine Efficacy against Anal Intraepithelial Neoplasia in Men Having Sex with Men - R Hillman
- 11.30-11.45 3. Burden of potentially HPV-associated oral cavity and oropharyngeal cancer in Australia - A Stein
- 11.45-12.00 4. Impact of quadrivalent HPV vaccine on genital warts in Australian general practice - E L Conway
- 12.00-12.15 5. Increasing burden of HPV-associated anal cancer in Australia - E L Conway
- 12.15-12.30 6. A Phase-III AS04 HPV-16/18 vaccine trial; implications for a school-girl HPV-vaccination program - W Tjalma

Rotavirus (Meeting Room 3) Chair: Paul Effler

- 11.00-11.15 1. Genotype distribution of rotavirus strains in Australian children after introduction of rotavirus vaccination program - C Kirkwood
- 11.15-11.30 2. Intussusception Post-Marketing Surveillance Following Rotavirus Vaccine Introduction in Australia - J Buttery
- 11.30-11.45 3. Gastroenteritis Admissions in Vaccinated and Unvaccinated Children Following Introduction of Rotavirus Vaccine - M Clarke
- 11.45-12.00 4. Rotavirus vaccine coverage and the impact of the vaccine on the timeliness of other NIP vaccines recommended at the same age - B Hull
- 12.00-12.15 5. Post-introduction observational research shows rotavirus vaccination program dramatically reduces disease in Queensland - S Lambert
- 12.15-12.30 6. An Update on RotaTeq™: Vaccine Effectiveness and Safety Evaluated in Routine Clinical Use - B Kuter

Conference Program

Pertussis (Meeting Room 10) Chair: Kristine Macartney

- 11.00-11.15 1. Decennial Administration of a Reduced-Antigen-Content dTpa Vaccine (Boostrix™) in Adults - R Booy
- 11.15-11.30 2. Long Term Immunity of Birth and One Month Old Acellular Pertussis (PA) Vaccine - N Wood
- 11.30-11.45 3. Pertussis in NSW: notifications and interventions - P Spokes
- 11.45-12.00 4. Impact of the national adolescent dTpa immunisation program - H Quinn
- 12.00-12.15 5. Impact of removal of the 18 month DTPa dose on pertussis vaccine effectiveness - H Quinn
- 12.15-12.30 6. Protecting infants from pertussis by immunising parents—a literature review - K Wiley

12.30-2.00 Lunch including Posters - Theme 1 - Quality in Service Delivery (Hall G)

2.00-3.30 Plenary 2 - Progress reports - vaccines (Hall B & C)

Chair: Dr Stephen Lambert

sponsored by Wyeth Vaccines-Australia

Dr Julia Brotherton - HPV vaccine in Australia: an update

Dr Kristine Macartney - Rotavirus vaccines in Australia: an update

Prof Peter McIntyre - Progress reports - Pertussis 2010

A/Prof Ross Andrews - Pneumococcal Diseases

3.30-4.00 Afternoon Tea (Hall G)

4.00-5.00 Concurrent Sessions 2

Human Papillomavirus 2 (Hall B & C) Chair: Rosemary Lester

- 4.00-4.15 1. Overcoming the challenges of educating mixed culture communities about HPV vaccines - M Heffernan
- 4.15-4.30 2. Influences on parents and their adolescent daughters with respect to Human Papillomavirus immunisation provided in school under the National Immunisation Program - W Bissinger
- 4.30-4.45 3. A national outcome: quadrivalent HPV vaccination and genital warts in Australia - B Donovan
- 4.45-5.00 4. Introduction of the Human Papillomavirus Vaccine in Fiji - K Jenkins

Varicella/Herpes Zoster (Meeting Room 1 & 2) Chair: Helen Marshall

- 4.00-4.15 1. The impact of varicella vaccination three years into a publicly funded program - A Heywood
- 4.15-4.30 2. Varicella-zoster in Victoria 1995-2007: varicella declined following vaccination whereas zoster increased beforehand - K Carville
- 4.30-4.45 3. Safety and Immunogenicity of Zoster Vaccine in Subjects With History of Zoster - J Grabenstein
- 4.45-5.00 4. Congenital and neonatal varicella: Impact of National Varicella Vaccination Program in Australia - G Khandaker

Aboriginal and Torres Strait Islander Peoples' Health (Meeting Room 3)

Chair: Ross Andrews

- 4.00-4.15 1. Indigenous Outreach Vaccination Programs – Barriers and Enablers - M Hall
- 4.15-4.30 2. Human Papillomavirus Vaccine: How effective is the uptake in Indigenous Australian Females? - T L Joseph
- 4.30-4.45 3. The Role of Health Promotion in Reducing Vaccine Preventable Disease among Indigenous Australians - S Jacobs
- 4.45-5.00 4. ***Check daily newsletter for details***

Service Delivery 1 (Meeting Room 10) Chair: Greg Rowles

- 4.00-4.15 1. Immunisation E Learning – “I have learnt more this way than ever before” - L Roberts
- 4.15-4.30 2. Implementation of a state-wide policy directive for mandatory immunisation of healthcare workers - J Leask
- 4.30-4.45 3. A decade of home visiting immunisation service - M Pellissier
- 4.45-5.00 4. Awareness and attitudes toward adult pertussis vaccination recommendations in parents and carers of four and five year old children - K Wiley

Conference Program

- 5.00-5.45 **Debate: "That we are too soft on the anti-vaccination lobby" (Hall B & C)**
Chair: Mr Michael Moore
- Speakers:** **Dr Paul Effler**
Dr Julie Leask
- 5.45-6.45 **Conference Reception (Hall G)**

Wednesday, 18 August

- 7.15-8.45 **Breakfast Forum: Making vaccine policy decisions (Hall A & D)**
Pre-registration required (see page 7 for information)
- 8.30 - 9.00 **Registration (Foyer G)**
- 9.00-10.30 **Plenary 3 - Global and Regional Issues in Immunisation (Hall B & C)**
Chair: A/Prof Peter Richmond
Sponsored by GlaxoSmithKline
- Dr Kate Taylor - Global Challenges in Immunization *or* Why Gates' New \$10 Billion is Not Enough**
Dr Supamit Chunsuttiwat - Abstract: TBA

10.30-11.00 Morning Tea (Hall G)

11.00-12.30 Concurrent Sessions 3

Pneumococcal Disease (Hall B & C) Chair: Ross Andrews

- 11.00-11.15 1. Serotype 19A, where to from here? - R Gilmour
- 11.15-11.30 2. Hyporesponsiveness to re-challenge dose following pneumococcal polysaccharide vaccine at 12 months of age, a randomized controlled trial - F Russell
- 11.30-11.45 3. Pneumococcal Nasopharyngeal Carriage Following A Reduced Dose 7-Valent Pneumococcal Conjugate Vaccine Schedule In Infancy And A 23-Valent Pneumococcal Polysaccharide Vaccine Booster, A Randomized Controlled Trial - F Russell
- 11.45-12.00 4. Implementation of the national childhood pneumococcal immunisation program: stakeholder perspectives - A Dey
- 12.00-12.15 5. Immune hyporesponsiveness following repeat pneumococcal polysaccharide vaccine (23vPPV) in Indigenous Australian adults and adolescents -S Skull
- 12.15-12.30 6. Multiple Doses of 23-Valent Pneumococcal Polysaccharide Vaccine (PN23) are Immunogenic in Adults - J Grabenstein

Viral Diseases (Meeting Room 1 & 2) Chair: Peter Richmond

- 11.00-11.15 1. Hospitalisation rates of seasonal influenza in non-Indigenous and Aboriginal and Torres Strait Islander children - C Chiu
- 11.15-11.30 2. Long-term antibody persistence following two and three-dose combined hepatitis vaccine in children - H Marshall
- 11.30-11.45 3. The impact of hepatitis A vaccination of Indigenous Australian children - R Menzies
- 11.45-12.00 4. Cost-effectiveness of hepatitis B vaccination in Australia - V Mogasale
- 12.00-12.15 5. Predictions of measles outbreak potential by division of general practice in Australia - J Wood
- 12.15-12.30 6. Seroprevalence of measles, mumps and rubella antibodies in the 2007 national serosurvey - J Wood

Conference Program

Knowledge, Attitudes and Practice (Meeting Room 3) Chair: Julie Leask

- 11.00-11.15 1. Australian Zoster study: GP and patient views about Herpes Zoster (Shingles), its complications, and the likely acceptance of a Zoster vaccine - J Litt
- 11.15-11.30 2. The Adolescent's Experience of School-based HPV Vaccination
- S Cooper Robbins
- 11.30-11.45 3. Caregivers' intentions regarding seasonal influenza and H1N1 vaccines for their children - Y K M Chow
- 11.45-12.00 4. Parents of children attending childcare – beliefs about seasonal and H1N1 influenza - C King
- 12.00-12.15 5. Parental Reporting of Adverse Events Following Immunisation - A Parrella
- 12.15-12.30 6. **Check daily newsletter for details**

Service Delivery 2 (Meeting Room 10) Chair: Helen Pitcher

- 11.00-11.15 1. A culturally appropriate model of immunisation for new arrival refugees in South Australia - L Clayton
- 11.15-11.30 2. Grubbsy's Immunisation Promotional Campaign – Evaluation - L Tomney
- 11.30-11.45 3. Accessing Immunisation for CALD Communities: Barriers and Enablers - L Schmidt
- 11.45-12.00 4. When opportunity knocks....Jab it? – Opportunistic immunising in the Emergency Department - L Philips
- 12.00-12.15 5. Logan City Primary School Catch-up Pilot Program - S Brown
- 12.15-12.30 6. **Check daily newsletter for details**

12.30-1.45 Lunch including Posters - Theme 2: Monitoring and Surveillance & Research (Hall G)

1.45-3.00 Plenary 4: Adverse Events Following Immunisation (Hall B & C)

Chair: Dr Kristine Macartney

Sponsored by The Australian Government Department of Health and Ageing

Dr Ruth Lopert - Large Population Interventions: Recent AEFI Challenges

Dr Jim Buttery & Dr Mike Gold - Vaccine Safety Surveillance – challenges for a new millennium

3.00-3.30 Afternoon Tea (Hall G)

3.30-5.00 Concurrent Sessions 4

Adverse Events (Hall B & C) Chair: Sue Campbell-Lloyd

- 3.30-3.45 1. Ten year clinic experience of adverse events following immunisation at The Children's Hospital at Westmead - N Wood
- 3.45-4.00 2. Trends in surveillance of adverse events following immunisation in Australia, 2000-2009 - D Mahajan
- 4.00-4.15 3. Is a Vaccine Injury Compensation Scheme overdue in Australia? - H Kelly
- 4.15-4.30 4. Surveillance of Adverse Events Following Immunisation (AEFI): The Model of SAEFVIC, Victoria - H Clothier
- 4.30-4.45 5. Estimating Background Rates of Potential Adverse Events Prior to H1N1 Vaccination, Australia - H Clothier
- 4.45-5.00 6. Syncope and Seizures following Human Papillomavirus Vaccination - N Crawford

Coverage/Data Linkage (Meeting Room 1 & 2) Chair: Maureen Watson

- 3.30-3.45 1. Legal impediments to data linkage: Remoto impedimento, emergit action*
- V Xafis
- 3.45-4.00 2. Travellers – a subgroup of highly vaccinated Australian adults? - A Heywood
- 4.00-4.15 3. A randomised trial of consent options in data linkage for vaccine surveillance
- J Berry
- 4.15-4.30 4. An Audit of Vaccination Status in Children with Inflammatory Bowel Disease
- N Crawford
- 4.30-4.45 5. Is Immunisation in Australia Really Multicultural? - K Cannings
- 4.45-5.00 6. Library Activities to Increase 4 yr old Vaccinations - A Nikitas

Conference Program

Cold Chain (Meeting Room 10) Chair: TBA

- 3.30-3.45 1. Factors affecting successful vaccine storage on the Central Coast of New South Wales - T Miles
- 3.45-4.00 2. Cold Chain: Are Current Purpose-Built Fridges Reducing Vaccine Losses?
- B MacDonald & S Almond
- 4.00-4.15 3. Providing RSV passive immunisation for high-risk infants during 2009 - J Royle
- 4.15-4.30 4. The problem with purpose built vaccine refrigerators - C Staples & P Cashman
- 4.30-4.45 5. Do purpose built vaccine refrigerators maintain their effectiveness over time?
- N Veselinovic
- 4.45-5.00 6. National Cold Chain Audit – Improving Effectiveness Reducing Waste - L Roberts

Bacterial Diseases (Meeting Room 3) Chair: Stephen Lambert

- 3.30-3.45 1. Predominance of Non-typeable Haemophilus Influenzae in Children With Recurrent Acute Otitis media - S Wiertsema
- 3.45-4.00 2. Immunogenicity and safety of the combined Hib-MenC-TT vaccine in Hib-primed/
MenC-unprimed toddlers - R Booy
- 4.00-4.15 3. Non-typeable haemophilus influenzae: predominant pathogen in middle ear effusion from otitis-prone children - L Kirkham
- 4.15-4.30 4. Hib disease in Indigenous Australian children, 1993-2008 - R Menzies
- 4.30-4.45 5. B-Cell Memory Six Years Following Serogroup C Meningococcal Conjugate Immunisation in Childhood - K Perrett
- 4.45-5.00 6. An Economic Evaluation of Pertussis Vaccination Strategies in Australia Using a Dynamic Compartmental Model - V Kirby

5.00-5.15 Short Break

5.15 - 6.00 Feery Oration: Science of Vaccines: Research, Subjectivity or Speculation - Professor Larry K. Pickering (Hall B & C)
Sponsored by CSL Biotherapies

6.00-10.00 Conference Dinner (Hall F)

Thursday, 19 August

8.30 - 9.00 Registration (Foyer G)

9.00-10.30 Plenary 5 - New vaccines - review of latest developments (Hall B & C)
Chair: Glen Mason
Sponsored by MAVIG

Prof C Raina MacIntyre - Herpes zoster vaccines
Prof Robert Booy - Influenza vaccines: new and old
Dr Helen Marshall - Combination vaccines: current use and future potential
Prof Elizabeth Miller - Meningococcal vaccines – past, present and future

10.30-11.00 Morning Tea (Hall G)

11.00-1.00 Plenary 6 - Immunisation Strategy (Hall B & C)
Chair:
Sponsored by CSL Biotherapies

Ms Jennifer Bryant & Ms Julianne Quaine - The National Immunisation Strategy
Dr Carmel Nelson - Abstract: TBA
Dr Steve Hambleton - Key considerations for the Immunisation Strategy
Dr David Isaacs - The role of the PBAC in vaccine policy

Panel: Ms Maureen Watson and Ms Karen Booth

1.00-2.00 Lunch (Hall G)

2.00-3.30 Conference Resolutions and Closing Session (Hall B & C)